Hip Pelvis.  2012 Dec;24(4):273-278. 10.5371/hp.2012.24.4.273.

Joint Preserving Non-surgical Treatment of Osteonecrosis of Femoral Head

• Lim YW
• Kim YS
• Kwon SY

• KMID: 1425042
• DOI: http://doi.org/10.5371/hp.2012.24.4.273

Abstract

A patient and physician initially consider how to preserve a joint, and make a goal to achieve this aim when osteonecrosis is initially diagnosed. On the other hand, it is almost impossible to make a decision with only a therapeutic approach based on the pathology, because osteonecrosis of the femoral head is caused by a range of factors. An objective prognosis has now become possible due to the development of radiologic diagnostic assessment tools, such as CT, bone scans and MRI. Most osteonecrosis patients are in their 20-50's. Therefore, physicians make a primary goal to control pain. The surgical approach, such as total joint replacement, is not the first option for early stage osteonecrosis. In the first stage, osteonecrosis should be treated to prevent secondary degenerative diseases and preserve the hip joint. This paper introduces a non-surgical joint preserving treatment in scientific and clinical aspects for early stage osteonecrosis.

Keyword

Osteonecrosis; Non-surgical treatment

MeSH Terms

Hand
Head
Hip Joint
Humans
Joints
Osteonecrosis
Prognosis

Reference

1. Lafforgue P, Dahan E, Chagnaud C, Schiano A, Kasbarian M, Acquaviva PC. Early-stage avascular necrosis of the femoral head: MR imaging for prognosis in 31 cases with at least 2 years of follow-up. Radiology. 1993. 187:199–204.

2. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am. 1995. 77:459–474.

3. Ohzono K, Saito M, Takaoka K, et al. Natural history of nontraumatic avascular necrosis of the femoral head. J Bone Joint Surg Br. 1991. 73:68–72.

4. Lieberman JR, Berry DJ, Mont MA, et al. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect. 2003. 52:337–355.

5. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002. 32:94–124.

6. Merle D'Aubigné R, Postel M, Mazabraud A, Massias P, Gueguen J, France P. Idiopathic necrosis of the femoral head in adults. J Bone Joint Surg Br. 1965. 47:612–633.

7. Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br. 1985. 67:3–9.

8. Hughes DE, MacDonald BR, Russel RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphophonates in long-term cultures of human bone marrow. J Clin Invest. 1989. 83:1930–1935.

9. Koo KH, Kim R. Quantifying the extent of osteonecrosis of the femoral head. A new method using MRI. J Bone Joint Surg Br. 1995. 77:875–880.

10. Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, Takaoka K. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci. 2002. 7:601–605.

11. Marcus ND, Enneking WF, Massam RA. The silent hip in idiopathic aseptic necrosis. Treatment by bone-grafting. J Bone Joint Surg Am. 1973. 55:1351–1366.

12. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br. 1995. 77:34–41.

13. Gardeniers JWM. Schoutens A, Arlet J, Gardeniers JWM, Hughes SPF, editors. The ARCO perspective for reaching one uniform staging system of osteonecrosis. Bone circulation and vascularization in normal and pathological conditions. 1993. New York: Plenum Press;375–380.

14. Hungerford DS, Jones LC. Asymptomatic osteonecrosis: should it be treated? Clin Orthop Relat Res. 2004. (429):124–130.

15. Nishii T, Sugano N, Ohzono K, Sakai T, Sato Y, Yoshikawa H. Significance of lesion size and location in the prediction of collapse of osteonecrosis of the femoral head: a new three-dimensional quantification using magnetic resonance imaging. J Orthop Res. 2002. 20:130–136.

16. Stulberg BN, Davis AW, Bauer TW, Levine M, Easley K. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clin Orthop Relat Res. 1991. (268):140–151.

17. Koo KH, Ahn IO, Kim R, et al. Bone marrow edema and associated pain in early stage osteonecrosis of the femoral head: prospective study with serial MR images. Radiology. 1999. 213:715–722.

18. Belmar CJ, Steinberg ME, Hartman-Sloan KM. Does pain predict outcome in hips with osteonecrosis? Clin Orthop Relat Res. 2004. (425):158–162.

19. Nam KW, Kim YL, Yoo JJ, Koo KH, Yoon KS, Kim HJ. Fate of untreated asymptomatic osteonecrosis of the femoral head. J Bone Joint Surg Am. 2008. 90:477–484.

20. Mont MA, Bezwada HP. Callaghan JJ, Rosenberg AG, editors. Osteonecrosis: strategies for treatment. The adult hip. 2007. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;477–499.

21. Cui Q, Wang GJ, Su CC, Balian G. The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Relat Res. 1997. (344):8–19.

22. Motomura G, Yamamoto T, Miyanishi K, Jingushi S, Iwamoto Y. Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Arthritis Rheum. 2004. 50:3387–3391.

23. Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus. 2006. 15:354–357.

24. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001. (386):173–178.

25. Yang C, Yang S, Du J, Li J, Xu W, Xiong Y. Vascular endothelial growth factor gene transfection to enhance the repair of avascular necrosis of the femoral head of rabbit. Chin Med J (Engl). 2003. 116:1544–1548.

26. Chen CH, Chang JK, Lai KA, Hou SM, Chang CH, Wang GJ. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012. 64:1572–1578.

27. Rajpura A, Wright AC, Board TN. Medical management of osteonecrosis of the hip: a review. Hip Int. 2011. 21:385–392.

28. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995. 17:137–144.

29. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995. 10:1478–1487.

30. Sahni M, Guencher HL, Fleish H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993. 91:2004–2011.

31. Astrand J, Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord. 2002. 3:19.

32. Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003. 18:2016–2022.

33. Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am. 2005. 87:550–557.

34. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005. 44:352–359.

35. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005. 87:2155–2159.

36. Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res. 2006. 443:273–279.

37. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007. 18:1363–1370.

38. Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis. Clin Orthop Relat Res. 2000. (370):295–310.

39. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005. (435):164–170.

40. Bassett CA, Schink-Ascani M, Lewis SM. Effects of pulsed electromagnetic fields on Steinberg ratings of femoral head osteonecrosis. Clin Orthop Relat Res. 1989. (246):172–185.

41. Massari L, Fini M, Cadossi R, Setti S, Traina GC. Biophysical stimulation with pulsed electromagnetic fields in osteonecrosis of the femoral head. J Bone Joint Surg Am. 2006. 88:Suppl 3. 56–60.

42. Reis ND, Schwartz O, Militianu D, et al. Hyperbaric oxygen therapy as a treatment for stage-I avascular necrosis of the femoral head. J Bone Joint Surg Br. 2003. 85:371–375.

43. Heinrichs W, Witzsch U, Bürger RA. [Extracorporeal shock-wave therapy (ESWT) for pseudoarthrosis. A new indication for regional anesthesia]. Anaesthesist. 1993. 42:361–364.

44. Ludwig J, Lauber S, Lauber HJ, Dreisilker U, Raedel R, Hotzinger H. High-energy shock wave treatment of femoral head necrosis in adults. Clin Orthop Relat Res. 2001. (387):119–126.

45. Wang CJ, Wang FS, Huang CC, Yang KD, Weng LH, Huang HY. Treatment for osteonecrosis of the femoral head: comparison of extracorporeal shock waves with core decompression and bone-grafting. J Bone Joint Surg Am. 2005. 87:2380–2387.

46. Katsube K, Bishop AT, Simari RD, Ylä-Herttuala S, Friedrich PF. Vascular endothelial growth factor (VEGF) gene transfer enhances surgical revascularization of necrotic bone. J Orthop Res. 2005. 23:469–474.